Christoph Thiemermann Selected Research

Peroxidase (Myeloperoxidase)

1/2022	Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice.
7/2013	Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse.
3/2013	Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow.
5/2010	Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury.
7/2006	Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma.
10/2005	Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia.
5/2005	Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury.
3/2005	Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury.
2/2005	Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
11/2004	Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christoph Thiemermann Research Topics

Disease

67	Inflammation (Inflammations) 01/2023 - 03/2000
52	Ischemia 03/2024 - 03/2002
48	Shock 03/2024 - 01/2002
48	Sepsis (Septicemia) 01/2023 - 11/2003
47	Reperfusion Injury 01/2024 - 01/2002
23	Endotoxemia 01/2020 - 03/2000
21	Wounds and Injuries (Trauma) 10/2023 - 08/2003
21	Multiple Organ Failure (MODS) 07/2023 - 01/2002
20	Hemorrhagic Shock 05/2024 - 09/2002
20	Necrosis 08/2010 - 01/2002
16	Septic Shock (Toxic Shock Syndrome) 01/2023 - 07/2002
12	Acute Kidney Injury (Acute Renal Failure) 01/2023 - 07/2002
12	Infarction (Infarctions) 10/2013 - 07/2002
11	Hemorrhage 07/2023 - 05/2002
11	Myocardial Infarction 01/2018 - 07/2002
10	Hypotension (Low Blood Pressure) 01/2023 - 04/2003
9	Infections 01/2023 - 09/2002
9	Critical Illness (Critically Ill) 01/2023 - 05/2006
9	Body Weight (Weight, Body) 09/2020 - 10/2002
9	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 07/2002
9	Hypoxia (Hypoxemia) 03/2013 - 08/2003
8	Lung Injury 03/2024 - 01/2002
8	Colitis 03/2024 - 02/2003
7	Obesity 01/2022 - 01/2013
6	Arthritis (Polyarthritis) 01/2024 - 10/2002
6	Pleurisy (Pleuritis) 01/2015 - 01/2002
6	Edema (Dropsy) 08/2008 - 05/2002
5	Insulin Resistance 01/2021 - 08/2010
5	Pneumonia (Pneumonitis) 01/2018 - 12/2010
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2013 - 02/2003
5	Experimental Arthritis 07/2006 - 01/2002
4	Cardiomyopathies (Cardiomyopathy) 01/2022 - 11/2016
4	Type 2 Diabetes Mellitus (MODY) 01/2022 - 03/2005

Drug/Important Bio-Agent (IBA)

26	LigandsIBA 05/2024 - 07/2002
23	CytokinesIBA 01/2022 - 03/2000
21	PPAR gammaIBA 08/2010 - 05/2002
19	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 03/2024 - 03/2000
19	Erythropoietin FDA Link 09/2013 - 07/2004
18	CreatinineIBA 09/2020 - 12/2002
16	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 05/2024 - 07/2002
16	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022 - 03/2000
16	EnzymesIBA 01/2022 - 01/2002
16	LipopolysaccharidesIBA 01/2020 - 04/2003
14	Glycogen Synthase (Synthase I)IBA 01/2024 - 03/2006
14	NF-kappa B (NF-kB)IBA 01/2023 - 01/2002
14	Peroxidase (Myeloperoxidase)IBA 01/2022 - 02/2003
14	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2007 - 12/2002
13	Alanine Transaminase (SGPT)IBA 01/2018 - 03/2004
11	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2023 - 01/2002
11	EndotoxinsIBA 01/2022 - 01/2002
10	Proteins (Proteins, Gene)FDA Link 01/2023 - 07/2002
10	InflammasomesIBA 01/2023 - 01/2013
10	Insulin (Novolin)FDA Link 01/2021 - 03/2005
9	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 03/2024 - 01/2002
9	Urea (Carbamide)FDA LinkGeneric 01/2023 - 12/2002
9	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2022 - 01/2002
9	Peptidoglycan (Murein)IBA 01/2020 - 07/2002
8	5-aminoisoquinolinoneIBA 03/2024 - 01/2002
8	(4- (((2- (3- fluoro- 4- (trifluoromethyl)phenyl)- 4- methyl- 1,3- thiazol- 5- yl)methyl)sulfanyl)- 2- methylphenoxy)acetic acidIBA 01/2018 - 02/2010
8	Transcription Factors (Transcription Factor)IBA 07/2017 - 01/2002
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2013 - 03/2000
8	DNA (Deoxyribonucleic Acid)IBA 03/2013 - 01/2002
8	PPAR-gamma AgonistsIBA 08/2010 - 08/2003
8	3-nitrotyrosineIBA 05/2010 - 05/2002
8	ZymosanIBA 02/2010 - 01/2002
8	4- benzyl- 2- methyl- 1,2,4- thiadiazolidine- 3,5- dioneIBA 01/2009 - 03/2006
7	Phosphotransferases (Kinase)IBA 01/2021 - 03/2012
7	Glycogen Synthase Kinase 3 betaIBA 09/2008 - 09/2005
7	Lipase (Acid Lipase)FDA Link 10/2005 - 05/2002
7	Rosiglitazone (Avandia)FDA Link 03/2005 - 07/2002
6	HDL LipoproteinsIBA 03/2024 - 07/2003
6	BilirubinIBA 01/2023 - 03/2004
6	salicylhydroxamic acid (SHAM)IBA 01/2020 - 02/2007
6	Caspase 3 (Caspase-3)IBA 12/2018 - 08/2003
6	CarrageenanIBA 01/2015 - 01/2002
6	Superoxide DismutaseIBA 09/2008 - 01/2002
6	Interleukin-1beta (Interleukin 1 beta)IBA 02/2008 - 03/2000
6	Malondialdehyde (Propanedial)IBA 03/2005 - 11/2002
5	9-deoxy-delta-9-prostaglandin D2IBA 05/2024 - 07/2002
5	Collagen Type II (Type II Collagen)IBA 01/2024 - 10/2002
5	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 01/2019
5	LipidsIBA 03/2021 - 01/2007
5	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 12/2013 - 05/2003
5	Glycogen Synthase KinasesIBA 05/2012 - 01/2007
5	PPAR alphaIBA 08/2010 - 07/2002
5	Interleukin-6 (Interleukin 6)IBA 08/2010 - 06/2002
5	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 02/2010 - 10/2005
5	SodiumIBA 03/2009 - 07/2002
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2008 - 01/2002
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2008 - 05/2005
5	Creatine Kinase (Creatine Phosphokinase)IBA 01/2007 - 03/2004
5	DinitrobenzenesIBA 01/2005 - 02/2003
4	acalabrutinibIBA 01/2023 - 01/2019
4	ibrutinibIBA 01/2023 - 01/2019
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 06/2007

Therapy/Procedure

37	Therapeutics 10/2023 - 01/2002
22	Resuscitation 03/2024 - 09/2002
17	Ligation 01/2023 - 08/2003
16	Punctures 01/2023 - 02/2006
7	Critical Care (Surgical Intensive Care) 10/2018 - 09/2004